... Summary: Genmab and GlaxoSmithKline Have Completed Recruitment of 66...COPENHAGEN Denmark November 28 /- Genmab A/S...Ofatumumab is an investigational fully human next generationmonoclo... We look forward to seeing the study results of the interim analysisf...

Summary: Genmab and GlaxoSmithKline Have Completed Recruitment of 66 CLL
Patients Respectively to Both Study Groups in a Pivotal Study of ofatumumab

COPENHAGEN, Denmark, November 28 /PRNewswire-FirstCall/ -- Genmab A/S
(OMX: GEN) announced today recruitment of 132 patients has been completed
in a pivotal study of ofatumumab (HuMax-CD20(R)) for the treatment of
refractory chronic lymphocytic leukemia (CLL). This cohort comprises 66
patients who are refractory to both fludarabine and alemtuzumab and 66
fludarabine refractory patients who are considered inappropriate candidates
for alemtuzumab due to bulky tumor in their lymph nodes. An interim
analysis will be conducted on this cohort when 24 week efficacy data are
available. The study will remain open for recruitment in order to collect
additional safety and efficacy data.

Ofatumumab is an investigational, fully human, next generation
monoclonal antibody that targets a unique epitope of the CD20 receptor on
the surface of b-cells. This epitope is different to the other anti-CD20
antibodies currently available or in development. Ofatumumab is being
developed under a co-development and commercialization agreement between
Genmab and GlaxoSmithKline.

"We look forward to seeing the study results of the interim analysis
from both patient groups. It is our hope, due to the high unmet need
amongst these patients, that registration may be possible in each
indication, depending on the data generated and ongoing discussions with
the regulatory authorities. Recruitment will continue to the trial," said
Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About the study

The study includes CLL patients who are refractory to both fludarabine
and alemtuzumab and patients who are refractory to fludarabine who are
considered inappropriate candidates for alemtuzumab due to bulky tumor in
their lymph nodes. Each group will be analyzed separately and it is hoped
that, registration of ofatumumab may be possible in each indication,
depending on the data generated from this study and the ongoing discussions
with the regulatory authorities.

All patients in the study will receive 8 weekly infusions of
ofatumumab, followed by 4 monthly infusions of ofatumumab. Patients will
receive 300 mg of ofatumumab at the first infusion and 2,000 mg of
ofatumumab at each subsequent infusion. Disease status will be assessed
every 4 weeks until week 28 and then every 3 months until disease
progression or month 24.

About Genmab

A/S Genmab is a leading international biotechnology company focused on
developing fully human antibody therapeutics for unmet medical needs. Using
unique, cutting-edge antibody technology, Genmab's world class discovery
and development teams have created and developed an extensive pipeline of
products for potential treatment of a variety of diseases including cancer
and autoimmune disorders. As Genmab advances towards a commercial future,
we remain committed to our primary goal of improving the lives of patients
who are in urgent need of new treatment options. For more information on
Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability
to manage growth, the competitive environment in relation to our business
area and markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and
other factors. Genmab is not under an obligation to up-date statements
regarding the future following the publication of this release; nor to
confirm such statements in relation to actual results, unless this is
required by law.

(Date:8/15/2017)... ... 15, 2017 , ... Nanomedical Diagnostics , a cutting-edge ... the launch of the new NHS Agile biosensor chip . The new ... a wide range of molecules, including small and large molecules, peptides, proteins, and ...

(Date:8/15/2017)... ... August 15, 2017 , ... Coffea arabica ... biotic and abiotic factors. During this educational webinar, participants will learn about the ... as gain a better understanding of how genomics is important for coffee breeding ...

(Date:8/10/2017)... Philadelphia, PA (PRWEB) , ... August 09, 2017 ... ... back to the classroom next week-- as students. From August 14th through the ... Institute. The institute, which debuted in the summer of 2016, provides Philadelphia-based middle ...

(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...

(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...